Company Ventures
ActiveFiled to raiseNew York, NYBiotechnology, Pharmaceuticals, HealthcareLast fund filed 2026
0 on a current fund
last 24 months
across filed funds
| Vehicle | Filed | Target | Sold to date | Investors |
|---|---|---|---|---|
| MTex Company | May 2026 | Indefinite | $27M | 22 |
| Company Ventures Fund IIIFiled to raise in 2026, with no closing reported yet. | 2026 | $80M | $0 | 0 |
| Company Ventures Terrarium Fund I | 2025 | $25M | $14M | 12 |
| Terrarium Studio Co Holdings | 2025 | $7.5M | $5.6M | 18 |
| Company Ventures Fund II-A |
Amounts are Item 13 as filed: the target is the whole offering, and the amount sold is cumulative across amendments rather than a final close. The filing carries no per-investor amount, so a firm’s own cheque is not recoverable here.
6 partners are named across this firm’s filings, 0 of them on a fund it is deploying now.
| Partner | Activity | Categories | Board seats | Last 24mo |
|---|---|---|---|---|
| Lucas WertheinNot on the current fund | Slowing | None listed | 1 |
Classified sectors of Company Ventures’s own portfolio companies, based on 6 with a verified or cited source.
Not a filing value: this is Lev’s own classification of each company, one company one vote regardless of how many of Company Ventures’s partners are named on its board, shown only when we found a specific, checkable source. Companies with no source read as unclassified and are left out of the shares above.
| Firm | Shared boards | Companies |
|---|---|---|
| KSN | 1 | Urigen Pharmaceuticals |
A shared board seat: a company where filings name a Company Ventures partner and a partner at the other firm, both with a clean identity match. Not a claim either firm led or co-led the round, only that both are named on the same board.
| May 2022 |
| $50M |
| $9.2M |
| 26 |
| Company Ventures Fund II | March 2022 | $50M | $16M | 29 |
| D. E. Shaw Employee Securities Company | June 2021 | Indefinite | $408M | 395 |
| Company Venture Capital Fund I | August 2018 | $60M | $30M | 78 |
| 1 |
| Mark RosenblumNot on the current fund | Slowing | Biotech & pharma, Medical devices | 5 | 1 |
| Matthew HarriganNot on the current fund | Slowing | Cybersecurity | 2 | 1 |
| Nelson SchubartNot on the current fund | Slowing | None listed | 1 | 1 |
| Noah WaxmanNot on the current fund | Slowing | None listed | 1 | 1 |
| Michael MilsteinNot on the current fund | Quiet | Robotics & hardware | 3 | 0 |
Activity is filed board seats in the last 24 months: 4+ Active, 2–3 Selective, 1 Slowing, none Quiet. A firm's tier totals its partners, so an active firm may be four partners with one seat each. It undercounts partners who invest without taking a board seat, and filings lag a closing by weeks, so Quiet means the paperwork is quiet, not the person.